(HealthDay)—The burden of hepatitis C virus (HCV) and associated disease is projected to remain considerable even in the era of oral direct-acting antivirals (DAAs), according to a study published online March 25 in Hepatology.

The Radiological Society of North America (RSNA) awarded Scott Gazelle with their 2015 Outstanding Research Award. 

The cost of treating hepatitis C (HCV) is likely to decline dramatically over the next decade in the United States, not because of cuts in drug prices but because the population in need of treatment will shrink by 2020 as a majority of patients will already have been treated, according to research by Jagpreet Chhatwal of Massachusetts General Hospital and colleagues presented at the 2015 AASLD Liver Meeting in San Francisco last month.

Continuous practice of Yoga and meditation can help one to reduce the need for healthcare services by 43%, says a new study by Harvard-affiliated Massachusetts General Hospital Institute for Technology Assessment and the Benson-Henry Institute.